Please use this identifier to cite or link to this item:
|Title:||Sox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia||Authors:||Zhang, H.
|Issue Date:||11-Nov-2013||Citation:||Zhang, H., Alberich-Jorda, M., Amabile, G., Yang, H., Staber, P.B., DiRuscio, A., Welner, R.S., Ebralidze, A., Zhang, J., Levantini, E., Lefebvre, V., Valk, P.J.M., Delwel, R., Hoogenkamp, M., Nerlov, C., Cammenga, J., Saez, B., Scadden, D.T., Bonifer, C., Ye, M., Tenen, D.G. (2013-11-11). Sox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia. Cancer Cell 24 (5) : 575-588. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ccr.2013.09.018||Abstract:||Mutation or epigenetic silencing of the transcription factor C/EBPα is observed in ~10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBPα whereby its expression is inversely correlated with C/EBPα activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBPα mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBPα inactivation contributes to the development of leukemia with a distinct LIC phenotype. © 2013 Elsevier Inc.||Source Title:||Cancer Cell||URI:||http://scholarbank.nus.edu.sg/handle/10635/125455||ISSN:||15356108||DOI:||10.1016/j.ccr.2013.09.018|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 23, 2021
WEB OF SCIENCETM
checked on Jul 15, 2021
checked on Jul 12, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.